Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S D Allen

Showing results (101-110 of 149) with videos related to

Pageof 15
Sort By:
Annals of the New York Academy of Sciences|January 1, 1988
cis-5-alkoxyalkyl-3-phenyl-3-(1H-imidazol-1-ylmethyl)-2- methylisoxazolidine derivativesD M Maryniak, G B Mullen, J T Mitchell, et al.
Annals of the New York Academy of Sciences|January 1, 1988
In vitro antifungal activity and structure-activity relationship studies of novel cis-5-acyloxyalkyl-3-phenyl-3-(1H-imidazol-1-ylmethyl)-2- methylisoxazolidine derivativesD M Maryniak, G B Mullen, S D Allen, et al.
Diagnostic Microbiology and Infectious Disease|July 1, 1991
Antimicrobial activity of cefpirome. An update compared to five third-generation cephalosporins against nearly 6000 recent clinical isolates from five medical centersR N Jones, M A Pfaller, S D Allen, et al.
The Journal of Antimicrobial Chemotherapy|February 1, 1996
In-vitro susceptibility of Streptococcus pneumoniae to the d- and l-isomers of ofloxacin: interpretive criteria and quality control limitsA L Barry, P C Fuchs, S D Allen, et al.
The Journal of Antimicrobial Chemotherapy|November 1, 1995
Tests for susceptibility of Streptococcus pneumoniae to cefdinir: proposed interpretive criteria and quality control parameters for both microdilution and disc diffusion methodsP C Fuchs, A L Barry, F C Tenover, et al.
Annals of the New York Academy of Sciences|January 1, 1988
In vitro antifungal activity of novel substituted 3,5-diphenyl-3-(1H-imidazol-1-ylmethyl)-2-methylisoxazolidine derivativesT R DeCory, G B Mullen, J T Mitchell, et al.
Journal of Medicinal Chemistry|October 1, 1988
Studies on antifungal agents. 23. Novel substituted 3,5-diphenyl-3-(1H-imidazol-1-ylmethyl)- 2-alkylisoxazolidine derivativesG B Mullen, T R DeCory, J T Mitchell, et al.
Journal of Clinical Microbiology|January 1, 1995
Interpretive criteria and quality control parameters for testing bacterial susceptibility to the fluoroquinolone PD131628A L Barry, P C Fuchs, S D Allen, et al.
Diagnostic Microbiology and Infectious Disease|March 1, 1993
Multilaboratory evaluation of the in vitro activity of 13 beta-lactam antibiotics against 1474 clinical isolates of aerobic and anaerobic bacteriaP R Murray, R N Jones, S D Allen, et al.
Antimicrobial Agents and Chemotherapy|August 1, 1993
Multicenter comparison of in vitro activities of FK-037, cefepime, ceftriaxone, ceftazidime, and cefuroximeJ A Washington, R N Jones, E H Gerlach, et al.
Pageof 15

Showing results (101-110 of 149) with videos related to

Sort By:
Pageof 15
Annals of the New York Academy of Sciences|January 1, 1988
cis-5-alkoxyalkyl-3-phenyl-3-(1H-imidazol-1-ylmethyl)-2- methylisoxazolidine derivativesD M Maryniak, G B Mullen, J T Mitchell, et al.
Annals of the New York Academy of Sciences|January 1, 1988
In vitro antifungal activity and structure-activity relationship studies of novel cis-5-acyloxyalkyl-3-phenyl-3-(1H-imidazol-1-ylmethyl)-2- methylisoxazolidine derivativesD M Maryniak, G B Mullen, S D Allen, et al.
Diagnostic Microbiology and Infectious Disease|July 1, 1991
Antimicrobial activity of cefpirome. An update compared to five third-generation cephalosporins against nearly 6000 recent clinical isolates from five medical centersR N Jones, M A Pfaller, S D Allen, et al.
The Journal of Antimicrobial Chemotherapy|February 1, 1996
In-vitro susceptibility of Streptococcus pneumoniae to the d- and l-isomers of ofloxacin: interpretive criteria and quality control limitsA L Barry, P C Fuchs, S D Allen, et al.
The Journal of Antimicrobial Chemotherapy|November 1, 1995
Tests for susceptibility of Streptococcus pneumoniae to cefdinir: proposed interpretive criteria and quality control parameters for both microdilution and disc diffusion methodsP C Fuchs, A L Barry, F C Tenover, et al.
Annals of the New York Academy of Sciences|January 1, 1988
In vitro antifungal activity of novel substituted 3,5-diphenyl-3-(1H-imidazol-1-ylmethyl)-2-methylisoxazolidine derivativesT R DeCory, G B Mullen, J T Mitchell, et al.
Journal of Medicinal Chemistry|October 1, 1988
Studies on antifungal agents. 23. Novel substituted 3,5-diphenyl-3-(1H-imidazol-1-ylmethyl)- 2-alkylisoxazolidine derivativesG B Mullen, T R DeCory, J T Mitchell, et al.
Journal of Clinical Microbiology|January 1, 1995
Interpretive criteria and quality control parameters for testing bacterial susceptibility to the fluoroquinolone PD131628A L Barry, P C Fuchs, S D Allen, et al.
Diagnostic Microbiology and Infectious Disease|March 1, 1993
Multilaboratory evaluation of the in vitro activity of 13 beta-lactam antibiotics against 1474 clinical isolates of aerobic and anaerobic bacteriaP R Murray, R N Jones, S D Allen, et al.
Antimicrobial Agents and Chemotherapy|August 1, 1993
Multicenter comparison of in vitro activities of FK-037, cefepime, ceftriaxone, ceftazidime, and cefuroximeJ A Washington, R N Jones, E H Gerlach, et al.
Pageof 15